The Ratings Game: Sarepta’s positive trial results for new DMD treatment could reopen rare disease drug controversy | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 6 September, 2017 by The TZ Newswire Staff

The Ratings Game: Sarepta’s positive trial results for new DMD treatment could reopen rare disease drug controversy

Sarepta shares surged as much as 14% on hopes that a new Duchenne muscular dystrophy drug could get faster-than-normal approval.
read more

See also
- Next Article Fintech Firm StreetShares Appoints Ed Walters As New Chief Marketing Officer
- Previous Article Facebook offers ‘hundreds of millions’ to labels and publishers for global licences
Editorial Calender

September 2017

M T W T F S S

1 2 3

4 5 6 7 8 9 10

11 12 13 14 15 16 17

18 19 20 21 22 23 24

25 26 27 28 29 30

« Aug Oct »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar